title: Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant.
abstract: Herpes simplex virus (HSV) causes serious problems in immuno-compromised patients such as those receiving a bone marrow transplant (BMT) for a hematological malignancy. Resistance to acyclovir (ACV) is a growing major concern. Foscarnet is a non-thymidine kinase-dependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach. We describe a girl treated with cidofovir for a life-threatening ACV-resistant HSV infection after an unrelated BMT for a relapse of an acute myeloblastic leukemia (AML).
authors.affiliation: Pediatrics, General Hospital, Sallanches, France.
authors.forename: N
authors.initials: N
authors.lastname: Blot
authors.forename: P
authors.initials: P
authors.lastname: Schneider
authors.forename: P
authors.initials: P
authors.lastname: Young
authors.forename: C
authors.initials: C
authors.lastname: Janvresse
authors.forename: D
authors.initials: D
authors.lastname: Dehesdin
authors.forename: P
authors.initials: P
authors.lastname: Tron
authors.forename: J P
authors.initials: JP
authors.lastname: Vannier
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use*; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D000212:Acyclovir